Daniel I. Chasman, PhD
Associate Professor of Medicine
Associate Geneticist
Brigham and Women’s Hospital
dchasman@bwh.harvard.edu
Dr. Chasman is an NIH-funded researcher interested in genome-wide genetic analysis of cardiometabolic traits and other related phenotypes. In particular, his research emphasizes genetic analysis of plasma lipid components, inflammatory biomarkers, pharmacogenetic response to statin therapy, incident vascular disease, and dietary preferences as related to cardiometabolic disease. In addition, he pursues a complementary interest in the genetics of migraine, a neurovascular condition. He is co-PI for the Women’s Genome Health Study (Buring, Lee, Ridker other PIs), a population of over 25,000 women with whole genome genotyping and over 25 years of follow-up for cardiovascular disease. He is also co-PI for genome-wide genetic analysis for JUPITER (Ridker, PI), a trial of rosuvastatin for primary prevention of cardiovascular disease.
AB: Harvard University
PhD: Stanford University
Full Listing of Publications
- Diagnosing migraine from genome-wide genotype data: a machine learning analysis May 6, 2025Migraine has an assumed polygenic basis, but the genetic risk variants identified in genome-wide association studies only explain a proportion of the heritability. We aimed to develop machine learning models, capturing non-additive and interactive effects, to address the missing heritability. This was a cross-sectional population-based study of participants in the second and third Trøndelag Health […]Antonios Danelakis
- Whole genome sequencing analysis of body mass index identifies novel African ancestry-specific risk allele April 11, 2025Obesity is a major public health crisis associated with high mortality rates. Previous genome-wide association studies (GWAS) investigating body mass index (BMI) have largely relied on imputed data from European individuals. This study leveraged whole-genome sequencing (WGS) data from 88,873 participants from the Trans-Omics for Precision Medicine (TOPMed) Program, of which 51% were of non-European […]Xinruo Zhang
- Statin effects on immunoglobulin-G glycomic architecture and the link to cardiovascular disease March 17, 2025CONCLUSION: High-intensity statin interventions decreased several specific IgG N-glycan levels without changing the overall architecture of IgG N-glycan connectivity. Two IgG N-glycans that were decreased by statins were inversely associated with CVD outcomes, suggesting that statins have effects on monosialylated and core fucosylated IgG N-glycans, which may affect their cardioprotective properties. These findings highlight a […]Azam Yazdani
- Age at Menarche and Coronary Artery Disease Risk: Divergent Associations with Different Sources of Variation March 10, 2025CONCLUSIONS: These results are consistent with earlier AAM causally increasing risk of CAD but suggest that later AAM itself does not cause increased risk of CAD; rather, sources of variation in AAM other than common genetic variants can cause both later AAM and increased risk of CAD. Dysglycemia, dyslipidemia, and central adiposity are candidate mediators […]Ambreen Sonawalla
- Sequencing in over 50,000 cases identifies coding and structural variation underlying atrial fibrillation risk March 6, 2025Atrial fibrillation (AF) is a prevalent and morbid abnormality of the heart rhythm with a strong genetic component. Here, we meta-analyzed genome and exome sequencing data from 36 studies that included 52,416 AF cases and 277,762 controls. In burden tests of rare coding variation, we identified novel associations between AF and the genes MYBPC3, LMNA, […]Seung Hoan Choi